Increasing women's choices in medical abortion: A study of misoprostol 400 μg swallowed immediately or held sublingually following 200 mg mifepristone

References

• United Nations Secretariat, Population Division of the Department of Economic and Social Affairs. Population Policy Data Bank
   Google Scholar
• Turkish Republic Ministry of Health, Mother and Child Health and Family Planning Directorate, State Planning Organisation and European Union. Turkish Demographic and Health Survey 2003. Hacettepe University Institute of Population Studies, , Ankara 2004
   Google Scholar
• Akın A, Enünlü T. Induced abortions in Turkey. Maternal health and family planning services and induced abortions in Turkey: Advanced analysis of the Turkish Population and Health Survey 1998. 1st edition. Hacettepe University, TAP foundation and UNFPA, Ankara 2002; 151–182
   Google Scholar
• Elul B, Hajri S, Ngoc N N, et al. Can women in less-developed countries use a simplified medical abortion regimen?. Lancet 2001; 357: 1402–1405
   PubMed Web of Science ®Google Scholar
• Blum J, Hajri S, Chélli H, et al. The medical abortion experiences of married and unmarried women in Tunis, Tunisia. Contraception 2004; 69: 63–69
   PubMed Web of Science ®Google Scholar
• Akin A, Blum J, Özalp S, et al. Results and lessons learned from a small medical abortion clinical study in Turkey. Contraception 2004; 70: 401–406
   PubMed Web of Science ®Google Scholar
• World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993; 307: 532–537
   PubMed Web of Science ®Google Scholar
• Ngoc N N, Nhan V Q, Blum J, et al. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. Br J Obstet Gynaecol 2004; 111: 814–819
   Google Scholar
• Clark W, Shannon C, Winikoff B. Misoprostol for uterine evacuation in induced abortion and pregnancy failure. Expert Rev Obstet Gynecol 2007; 2: 67–108
   Google Scholar
• Bracken H, Gliozheni O, Kati K, et al. Mifepristone medical abortion in Albania: Results from a pilot clinical research study. Eur J Contracept Reprod Health Care 2006; 11: 38–46
   PubMed Web of Science ®Google Scholar
• Clark W H, Hassoun D, Gemzell-Danielsson K, et al. Home use of two doses of misoprostol after mifepristone for medical abortion: A pilot study in Sweden and France. Eur J Contracept Reprod Health Care 2005; 10: 184–189
   PubMed Web of Science ®Google Scholar
• Guengant J P, Bangou J, Elul B. Mifepristone-misoprostol medical abortion: Home administration of misoprostol in Guadeloupe. Contraception 1999; 60: 167–172
   PubMed Web of Science ®Google Scholar
• Schaff E A, Fielding S L, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 2001; 64: 81–85
   PubMed Web of Science ®Google Scholar
• Schaff E A, Fielding S L, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mcg for abortion up to 63 days of pregnancy. Contraception 2002; 66: 247–250
   PubMed Web of Science ®Google Scholar
• Middleton T, Schaff E, Fielding S L, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005; 72: 328–332
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok P W, Dow J, et al. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception 2003; 68: 335–338
   PubMed Web of Science ®Google Scholar
• Tang O S, Xu J, Cheng L, et al. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum Reprod 2002; 17: 1738–1740
   PubMed Web of Science ®Google Scholar
• Tang O S, Chan C C, Ng E H, et al. A prospective, randomized, placebo controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortion of less than 9 weeks gestation. Human Reprod 2003; 18: 2315–2318
   PubMed Web of Science ®Google Scholar
• Singh K C, Ummat S, Rajaram S, et al. First trimester abortion with mifepristone and three doses of sublingual misoprostol: A pilot study. Aust NZ J Obstet Gynaecol 2005; 45: 495–498
   PubMed Web of Science ®Google Scholar
• Tang O S, Schweer H, Seyberth H W, et al. Pharmacokinetics of different routes of administration of misoprostol. Human Reprod 2002; 17: 332–336
   PubMed Web of Science ®Google Scholar
• Rorbye C, Norgaard M, Vestermark V, et al. Medical abortion: defining success and categorizing failures. Contraception 2003; 68: 247–251
   PubMed Web of Science ®Google Scholar
• Rorbye C, Norgaard M, Vestermark V, et al. Prediction of late failure after medical abortion from serial B-hCG measurements and ultrasonography. Hum Reprod 2004; 19: 85–89
   PubMed Web of Science ®Google Scholar
• Akın A., Dogan G B, Dilbaz B, et al. Medical abortion is a new choice for Turkey. Hacettepe University Medical Faculty Public Health Department, Ankara 2005
   Google Scholar